Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.8 EUR | -6.81% | -3.73% | +70.99% |
15/05 | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
09/05 | Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+70.99% | 1.69B | |
+9.84% | 118B | |
+10.62% | 106B | |
-10.87% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.46% | 15.97B | |
+6.87% | 14.03B | |
+17.74% | 11.67B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target